Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude

Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nocicepti...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of neuroscience Vol. 35; no. 26; pp. 9580 - 9594
Main Authors Gerhold, K. J., Drdla-Schutting, R., Honsek, S. D., Forsthuber, L., Sandkuhler, J.
Format Journal Article
LanguageEnglish
Published United States Society for Neuroscience 01.07.2015
Subjects
Online AccessGet full text
ISSN0270-6474
1529-2401
1529-2401
DOI10.1523/JNEUROSCI.0731-14.2015

Cover

Abstract Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 μg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis.
AbstractList Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo . At an analgesically active dose of 1500 μg·kg −1 , buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ 1 -opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ 1 -opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg −1 ), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT 2 Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis.
Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 μg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis.Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 μg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis.
Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 μg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis.
Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 mu g times kg super(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively mu sub(1)-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective mu sub(1)-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 mu g times kg super(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive mu -opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT sub(2)Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct mu -opioid receptor subtypes located at different levels of the neuraxis.
Author Drdla-Schutting, R.
Gerhold, K. J.
Honsek, S. D.
Sandkuhler, J.
Forsthuber, L.
Author_xml – sequence: 1
  givenname: K. J.
  surname: Gerhold
  fullname: Gerhold, K. J.
– sequence: 2
  givenname: R.
  surname: Drdla-Schutting
  fullname: Drdla-Schutting, R.
– sequence: 3
  givenname: S. D.
  surname: Honsek
  fullname: Honsek, S. D.
– sequence: 4
  givenname: L.
  surname: Forsthuber
  fullname: Forsthuber, L.
– sequence: 5
  givenname: J.
  surname: Sandkuhler
  fullname: Sandkuhler, J.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26134641$$D View this record in MEDLINE/PubMed
BookMark eNqFUl1vEzEQtFARTQt_ofIjLxfs81dPQkglpLSoENTSZ8ux9xKji33Yd5H4Cf3XdWiJCi998mp2ZnZXniN0EGIAhE4omVJRs3dfvs1vrxc3s8spUYxWlE9rQsULNCndpqo5oQdoQmpFKskVP0RHOf8khChC1St0WEvKuOR0gu6-pxii9Rb6wW8Bm-DwWRj8U2zetmCHjGOLP459ghBTv_YBsA94WAO-6X0wHZ7F5PCnmHKpL2IKBdhCwqZgGfC1CSvYWZzHMeFFcpD-OH41q-CH0cFr9LI1XYY3j-8xuj2f_5hdVFeLz5ezs6vKcq6GCrhoFBXKqdNaEOesbJeULYERx5eS0VJJUQtqGRDBnDCGnBbAgbUOagnsGH148O3H5QachTAk0-k--Y1Jv3U0Xv_bCX6tV3GruShzCSkGbx8NUvw1Qh70xmcLXWcCxDFrqmolm4bV8nmqbJiiDVe0UE-errXf5-9XFYJ8INgUc07Q7imU6F0m9D4TepcJTbneZaII3_8ntH4wg4-783z3nPweXCO_tg
CitedBy_id crossref_primary_10_1038_s41386_021_01200_5
crossref_primary_10_1038_s41598_021_88030_z
crossref_primary_10_1186_s44158_024_00201_2
crossref_primary_10_1038_s41598_017_11120_4
crossref_primary_10_1007_s40122_019_00143_6
crossref_primary_10_1038_s41598_017_02509_2
crossref_primary_10_1002_ejp_1328
crossref_primary_10_1016_j_brainres_2021_147445
crossref_primary_10_1016_j_pnpbp_2019_02_010
crossref_primary_10_3389_fimmu_2020_00300
crossref_primary_10_1016_j_neuroscience_2016_06_029
crossref_primary_10_1152_jn_00680_2016
crossref_primary_10_1007_s40265_018_0953_z
crossref_primary_10_1113_JP283021
crossref_primary_10_1016_j_peptides_2016_12_004
crossref_primary_10_1523_JNEUROSCI_1182_22_2022
crossref_primary_10_1002_ame2_12157
ContentType Journal Article
Copyright Copyright © 2015 Gerhold, Drdla-Schutting et al.
Copyright © 2015 Gerhold, Drdla-Schutting et al. 2015
Copyright_xml – notice: Copyright © 2015 Gerhold, Drdla-Schutting et al.
– notice: Copyright © 2015 Gerhold, Drdla-Schutting et al. 2015
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7TK
7U7
C1K
5PM
DOI 10.1523/JNEUROSCI.0731-14.2015
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Neurosciences Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Toxicology Abstracts
Neurosciences Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Toxicology Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1529-2401
EndPage 9594
ExternalDocumentID PMC4571500
26134641
10_1523_JNEUROSCI_0731_14_2015
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-DZ
-~X
.55
18M
2WC
34G
39C
53G
5GY
5RE
5VS
AAFWJ
AAJMC
AAYXX
ABBAR
ABIVO
ACGUR
ACNCT
ADBBV
ADCOW
ADHGD
AENEX
AETEA
AFCFT
AFOSN
AFSQR
AHWXS
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
H13
HYE
H~9
KQ8
L7B
OK1
P0W
P2P
QZG
R.V
RHI
RPM
TFN
TR2
W8F
WH7
WOQ
X7M
XJT
YBU
YHG
YKV
YNH
YSK
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7TK
7U7
C1K
5PM
ID FETCH-LOGICAL-c447t-e4597157d78250ddc6fb13be30d4b631be365251c3e053d5aa08652deccde26e3
ISSN 0270-6474
1529-2401
IngestDate Thu Aug 21 14:04:55 EDT 2025
Fri Sep 05 06:21:33 EDT 2025
Fri Sep 05 07:34:27 EDT 2025
Thu Apr 03 07:00:55 EDT 2025
Thu Apr 24 23:12:29 EDT 2025
Tue Jul 01 03:47:24 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 26
Keywords descending facilitation
pain
buprenorphine
spinal cord
synapse
opioid
Language English
License Copyright © 2015 Gerhold, Drdla-Schutting et al.
This article is freely available online through the J Neurosci Author Open Choice option.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c447t-e4597157d78250ddc6fb13be30d4b631be365251c3e053d5aa08652deccde26e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
K.J.G. and R.D.-S. contributed equally to this work.
Author contributions: K.J.G., R.D.-S., and J.S. designed research; K.J.G., R.D.-S., S.D.H., and L.F. performed research; K.J.G. and R.D.-S. analyzed data; K.J.G., R.D.-S., and J.S. wrote the paper.
ORCID 0000-0003-0645-986X
0000-0002-5209-485X
OpenAccessLink https://www.jneurosci.org/content/jneuro/35/26/9580.full.pdf
PMID 26134641
PQID 1693719471
PQPubID 23479
PageCount 15
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4571500
proquest_miscellaneous_1727699326
proquest_miscellaneous_1693719471
pubmed_primary_26134641
crossref_primary_10_1523_JNEUROSCI_0731_14_2015
crossref_citationtrail_10_1523_JNEUROSCI_0731_14_2015
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-07-01
2015-Jul-01
20150701
PublicationDateYYYYMMDD 2015-07-01
PublicationDate_xml – month: 07
  year: 2015
  text: 2015-07-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of neuroscience
PublicationTitleAlternate J Neurosci
PublicationYear 2015
Publisher Society for Neuroscience
Publisher_xml – name: Society for Neuroscience
SSID ssj0007017
Score 2.2773461
Snippet Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 9580
SubjectTerms Analgesics, Opioid - pharmacology
Animals
Animals, Newborn
Astrocytes - drug effects
Buprenorphine - pharmacology
Dose-Response Relationship, Drug
Hyperalgesia - drug therapy
In Vitro Techniques
Male
Naloxone - analogs & derivatives
Naloxone - pharmacology
Nerve Fibers, Unmyelinated - drug effects
Nerve Fibers, Unmyelinated - metabolism
Pain Measurement - drug effects
Pain Threshold - drug effects
Phosphopyruvate Hydratase - metabolism
Rats
Rats, Sprague-Dawley
Signal Transduction - drug effects
Spinal Cord - cytology
Spinal Nerve Roots - cytology
Synapses - drug effects
Time Factors
Title Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude
URI https://www.ncbi.nlm.nih.gov/pubmed/26134641
https://www.proquest.com/docview/1693719471
https://www.proquest.com/docview/1727699326
https://pubmed.ncbi.nlm.nih.gov/PMC4571500
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFAePScZGREC9Vsiaxk-axdCulwLh0k_YWxYmjVhrJlCZI8A_4d_wkzrEzN-mmwXiJUic-dXy-HJ8Tnwshr0Ivi1niCNxhHFkM-GCNXDGyYLFlgsV-OOIYjfzxyJ-dsPkpP-31fre8lupK2MnPK-NK_oer0AZ8xSjZG3DWEIUGOAf-whE4DMd_4vHnsshhcpVnyne9DzDGyg-ttsONv8abGvNXFjCxK50qBHXOxbkqizXBqMGDolyrUiIlRgLCbAxiaFvLwVeMQEASUxjV4BNm62x8Z9D3qE477kSbYDOl5rYSZhoMvZXlsqlW_d4ezG2jTZfpWWwtkmWtvLEV-83FGfp9K9m9sAcHpnkKg66WtdDQ-2C3P2M43Li8Xkg7NwA7lumSPbZspLGrtn-ctrjW2U0aWLpt4RtyXRSqWchDrssnX1okuEpWMT9CX8nF5J0NUs6xHPzApiNLu1m5t1ZL48OI1hNQigydCOmAKRUhnVvkthuANoduAl82-euDoaoBbR62iVkHOvtXj6erLl2ygbZdeVu60fE9crfhNh1rhN4nPZk_ILvjPK6Kbz_oa6rcjNX-zS751QUtBdDSLdDSBrS0yGgHtHSVUwAt1aClCFqqQUsRtFSBlsYUQUsVaJEEgpZq0OJPA9qH5GR6eDyZWU09ECthLKgsycD6dXiQglbLh2ma-JlwPCG9YcqE7zlw5nPQ1xMP652kPI7BXuduClIqla4vvUdkJy9y-YRQ13WGSSwCsNZc5o38MGHCk2AcDTORcZH1Cb-Y9ihpkuVjzZaz6Hq298m-6Xeu08X8tcfLC65GINlxuy7OZVGvI0yTFDghaI_X3APmhx-iDdYnjzUSzP-6oKkzn0HvoIMRcwNmlu9eyVdLlWGe8QDnYu_GT_OU3Nm83M_ITlXW8jlo7ZV4oV6EPy7O6ec
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pronociceptive+and+Antinociceptive+Effects+of+Buprenorphine+in+the+Spinal+Cord+Dorsal+Horn+Cover+a+Dose+Range+of+Four+Orders+of+Magnitude&rft.jtitle=The+Journal+of+neuroscience&rft.au=Gerhold%2C+K.+J.&rft.au=Drdla-Schutting%2C+R.&rft.au=Honsek%2C+S.+D.&rft.au=Forsthuber%2C+L.&rft.date=2015-07-01&rft.issn=0270-6474&rft.eissn=1529-2401&rft.volume=35&rft.issue=26&rft.spage=9580&rft.epage=9594&rft_id=info:doi/10.1523%2FJNEUROSCI.0731-14.2015&rft.externalDBID=n%2Fa&rft.externalDocID=10_1523_JNEUROSCI_0731_14_2015
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-6474&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-6474&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-6474&client=summon